New data demonstrates Sandoz’ etanercept and rituximab biosimilar candidates bioequivalent to originator products

  • Sandoz’ biosimilar etanercept candidate shows pharmacokinetic (PK) bioequivalence with no clinically meaningful differences in safety, tolerability and immunogenicity to the originator.1

  • Sandoz’ biosimilar rituximab candidate shows PK bioequivalence and similar pharmacodynamics (PD), safety, efficacy and immunogenicity.2

  • Biosimilar etanercept candidate is under regulatory review by EMA* and FDA** and biosimilar rituximab candidate is undergoing EMA review.

Holzkirchen, June 9, 2016 – Sandoz, a …

/by